Genetic and epigenetic alterations in pancreatic carcinogenesis

Yannick Delpu, Naïma Hanoun, Hubert Lulka, Flavie Sicard, Janick Selves, Louis Buscail, Jérôme Torrisani, Pierre Cordelier, Yannick Delpu, Naïma Hanoun, Hubert Lulka, Flavie Sicard, Janick Selves, Louis Buscail, Jérôme Torrisani, Pierre Cordelier

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.

Keywords: Cancer; DNA methylation; Genetic alteration.; Pancreas; Preneoplastic lesions.

Figures

Fig. (1)
Fig. (1)
Microscopic view of Pancreatic intraepithelial neoplasia.
Fig. (2)
Fig. (2)
A: Macroscopic view of an Intraductal Papillary Mucinous Neoplasm. B: Microscopic view of an Intraductal Papillary Mucinous Neoplasm.
Fig. (3)
Fig. (3)
A: Macroscopic view of Mucinous Cystic Neoplasm. B: Microscopic view of Mucinous Cystic Neoplasm.

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009. CA Cancer J. Clin. 2009;59:225–249.
    1. Koorstra J B, Hustinx S R, Offerhaus G J, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110–125.
    1. Ghaneh P, Costello E, Neoptolemos J P. Biology and management of pancreatic cancer. Gut. 2007;56:1134–1152.
    1. Brat D J, Lillemoe K D, Yeo C J, Warfield P B, Hruban R H. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 1998;22:163–169.
    1. Hruban R H, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int. J. Clin. Exp. Pathol. 2008;1:306–316.
    1. Sipos B, Frank S, Gress T, Hahn S, Kloppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology. 2009;9:45–54.
    1. Yamaguchi K, Yokohata K, Noshiro H, Chijiiwa K, Tanaka M. Mucinous cystic neoplasm of the pancreas or intraductal papillary-mucinous tumour of the pancreas. Eur. J. Surg. 2000;166:141–148.
    1. Andea A, Sarkar F, Adsay V N. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod. Pathol. 2003;16:996–1006.
    1. Terhune P G, Phifer D M, Tosteson T D, Longnecker D S. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol. Biomarkers Prev. 1998;7:515–521.
    1. Hingorani S R, Petricoin E F, Maitra A, Rajapakse V, King C, Jacobetz M A, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450.
    1. Roggin K K, Chennat J, Oto A, Noffsinger A, Briggs A, Matthews J B. Pancreatic cystic neoplasm. Curr. Probl. Surg. 0000;47:459–510.
    1. Schonleben F, Qiu W, Bruckman K C, Ciau N T, Li X, Lauerman M H, Frucht H, Chabot JA, Allendorf JD, Re-motti HE, Su GH. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2007;249:242–248.
    1. Yonezawa S, Higashi M, Yamada N, Goto M. Precursor lesions of pancreatic cancer. Gut Liver. 2008;2:137–154.
    1. Hruban R H, Adsay N V. Molecular classification of neoplasms of the pancreas. Hum. Pathol. 2009;40:612–623.
    1. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.
    1. Maire F, Hammel P, Terris B, Paye F, Scoazec J Y, Cellier C, Barthet M, O'Toole D, Rufat P, Partensky C, Cuillerier E, Lévy P, Belghiti J, Ruszniewski P. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51:717–722.
    1. Siveke J T, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, Schmid R M. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell. 2007;12:266–279.
    1. Wilentz R E, Albores-Saavedra J, Hruban R H. Mucinous cystic neoplasms of the pancreas. Semin. Diagn. Pathol. 2000;17:31–42.
    1. Hruban R H, Maitra A, Kern S E, Goggins M. Precursors to pancreatic cancer. Gastroenterol. Clin. North Am. 2007;36:831–849.
    1. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11:229–243.
    1. Jensen J N, Cameron E, Garay M V, Starkey T W, Gianani R, Jensen J. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology. 2005;128:728–741.
    1. Sergeant G, Vankelecom H, Gremeaux L, Topal B. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat. Rev. Clin. Oncol. 2009;6:580–586.
    1. Bhagwandin V J, Shay J W. Pancreatic cancer stem cells: fact or fiction? Biochim. Biophys. Acta. 2009;1792:248–259.
    1. Lee C J, Dosch J, Simeone D M. Pancreatic cancer stem cells. J. Clin. Oncol. 2008;26:2806–2812.
    1. Hermann P C, Mueller M T, Heeschen C. Pancreatic cancer stem cells--insights and perspectives. Expert Opin. Biol. Ther. 2009;9:1271–1278.
    1. Simeone D M. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin. Cancer Res. 2008;14:5646–5648.
    1. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–1037.
    1. Zhou J, Wang CY, Liu T, Wu B, Zhou F, Xiong JX, Wu HS, Tao J, Zhao G, Yang M, Gou SM. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 2008;14:925–930.
    1. Iovanna J L, Lechene de la Porte P, Dagorn J C. Expression of genes associated with dedifferentiation and cell proliferation during pancreatic regeneration following acute pancreatitis. Pancreas. 1992;7:712–718.
    1. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc. Natl. Acad. Sci. USA. 1986;83:5141–5144.
    1. Papageorgio C, Perry M C. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Cancer Invest. 2007;25:647–657.
    1. Dancer J, Takei H, Ro J Y, Lowery-Nordberg M. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization. Oncol. Rep. 2007;18:151–155.
    1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gal-linger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007;25:1960–1966.
    1. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004;22:2610–2616.
    1. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 2006;12:4283–4287.
    1. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S, Baba H, Yamamura K. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol. Cancer Res. 2009;7:1572–1581.
    1. Kirby R E, Lewandrowski K B, Southern J F, Compton C C, Warshaw A L. Relation of epidermal growth factor receptor and estrogen receptor-independent pS2 protein to the malignant transformation of mucinous cystic neoplasms of the pancreas. Arch. Surg. 1995;130:69–72.
    1. Aguirre A J, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N, Cauwels C, Cordon-Cardo C, Redston MS, DePinho RA, Chin L. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc. Natl. Acad. Sci. USA. 2004;101:9067–9072.
    1. Lucito R, Suresh S, Walter K, Pandey A, Lakshmi B, Kras-nitz A, Sebat J, Wigler M, Klein AP, Brune K, Palmisano E, Maitra A, Goggins M, Hruban RH. Copy-number variants in patients with a strong family history of pancreatic cancer. Cancer Biol. Ther. 2007;6:1592–1599.
    1. Campbell P J, Yachida S, Mudie L J, Stephens P J, Pleas-ance E D, Stebbings L A, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109–1113.
    1. Lujambio A, Calin G A, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA. 2008;105:13556–13561.
    1. Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
    1. Rachagani S, Kumar S, Batra S K. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett. 2010;292:8–16.
    1. Zhang Y, Li M, Wang H, Fisher W E, Lin P H, Yao Q, Chen C. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J. Surg. 2009;33:698–709.
    1. Calin G A, Sevignani C, Dumitru C D, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA. 2004;101:2999–3004.
    1. Feldmann G, Beaty R, Hruban R H, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J. Hepatobiliary Pancreat. Surg. 2007;14:224–232.
    1. Habbe N, Shi G, Meguid R A, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers DA, Konieczny SF, Leach SD, Maitra A. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. USA. 2008;105:18913–18918.
    1. Schonleben F, Allendorf J D, Qiu W, Li X, Ho D J, Ciau N T, Fine RL, Chabot JA, Remotti HE, Su GH. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2008;36:168–172.
    1. Jimenez R E, Warshaw A L, Z'Graggen K, Hartwig W, Tay-lor D Z, Compton C C, Fernández-del Castillo C. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann. Surg. 1999;230:501–509.
    1. Ishimura N, Yamasawa K, Karim Rumi M A, Kadowaki Y, Ishihara S, Amano Y, Nio Y, Higami T, Kinoshita Y. BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett. 2003;199:169–173.
    1. Calhoun E S, Jones J B, Ashfaq R, Adsay V, Baker S J, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am. J. Pathol. 2003;163:1255–1260.
    1. Chadwick B, Willmore-Payne C, Tripp S, Layfield L J, Hirschowitz S, Holden J. Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. Appl. Immunohistochem. Mol. Morphol. 2009;17:31–39.
    1. Biankin A V, Biankin S A, Kench J G, Morey A L, Lee C S, Head D R, Eckstein RP, Hugh TB, Henshall SM, Sutherland RL. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50:861–868.
    1. Sorio C, Capelli P, Lissandrini D, Moore P S, Balzarini P, Falconi M, Zamboni G, Scarpa A. Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. Virchows Arch. 2005;446:239–245.
    1. Iacobuzio-Donahue C A, Klimstra D S, Adsay N V, Wilentz R E, Argani P, Sohn T A, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am. J. Pathol. 2000;157:755–761.
    1. Yachida S, Iacobuzio-Donahue C A. The pathology and genetics of metastatic pancreatic cancer. Arch. Pathol. Lab. Med. 2009;133:413–422.
    1. Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am. J. Surg. Pathol. 2002;26:466–471.
    1. Flejou J F, Boulange B, Bernades P, Belghiti J, Henin D. p53 protein expression and DNA ploidy in cystic tumors of the pancreas. Pancreas. 1996;13:247–252.
    1. Petersen G M, Amundadottir L, Fuchs C S, Kraft P, Stolzenberg-Solomon R Z, Jacobs K B, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF, Hoover RN, Jr, Hartge P, Chanock SJ. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 2010;42:224–228.
    1. Weber M. [Profiles of DNA methylation in normal and cancer cells] Med Sci (Paris) 2008;24:731–734.
    1. Robertson K D, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales F A, Jones PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27:2291–2298.
    1. Peng D F, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kosuge T, Hirohashi S. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci. 2005;96:403–408.
    1. Ueki T, Toyota M, Sohn T, Yeo C J, Issa J P, Hruban R H, Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835–1839.
    1. Sato N, Maitra A, Fukushima N, van Heek N T, Matsubayashi H, Iacobuzio-Donahue C A, Rosty C, Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003;63:4158–4166.
    1. Hervouet E, Vallette F M, Cartron P F. Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics. 2009;4:487–499.
    1. Ueki T, Toyota M, Skinner H, Walter K M, Yeo C J, Issa J P, Hruban RH, Goggins M. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 2001;61:8540–8546.
    1. Tan A C, Jimeno A, Lin S H, Wheelhouse J, Chan F, Solo-mon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol. Oncol. 2009;3:425–438.
    1. Omura N, Li C P, Li A, Hong S M, Walter K, Jimeno A, Hidalgo M, Goggins M. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol. Ther. 2008;7:1146–1156.
    1. Klump B, Hsieh C J, Nehls O, Dette S, Holzmann K, Kiesslich R, Jung M, Sinn U, Otner M, Porschen R, Gregor M. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br. J. Cancer. 2003;88:217–222.
    1. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang-Vu C. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene. 2003;22:3806–3812.
    1. Kuroki T, Tajima Y, Kanematsu T. Role of hypermethylation on carcinogenesis in the pancreas. Surg. Today. 2004;34:981–986.
    1. Sato N, Fukushima N, Hruban R H, Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod. Pathol. 2008;21:238–244.
    1. Sato N, Goggins M. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J. Hepatobiliary Pancreat. Surg. 2006;13:280–285.
    1. Hanoun N, Delpu Y, Suriawinata A A, Bournet B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L, Cordelier P, Torrisani J. The silencing of MicroRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 2010;56:1107–1118.
    1. Lee K H, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology. 2009;9:293–301.
    1. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–2600.
    1. Li A, Omura N, Hong S M, Vincent A, Walter K, Griffith M, Borges M, Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010;70:5226–5237.
    1. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816.
    1. Mu P, Han Y C, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23:2806–2811.
    1. Xiao C, Srinivasan L, Calado D P, Patterson H C, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. Lymphopro-liferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008;9:405–414.
    1. Medina P P, Nolde M, Slack F J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467:86–90.
    1. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl. Acad. Sci. USA. 2006;103:7024–7029.
    1. Bournet B, Souque A, Senesse P, Assenat E, Barthet M, Lesavre N, Aubert A, O'Toole D, Hammel P, Levy P, Ruszniewski P, Bouisson M, Escourrou J, Cordelier P, Buscail L. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy. 2009;41:552–557.
    1. Hosoda W, Takagi T, Mizuno N, Shimizu Y, Sano T, Yamao K, Yatabe Y. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol. Int. 2010;60:358–364.
    1. Jang J Y, Park Y C, Song Y S, Lee S E, Hwang D W, Lim C S, Lee HE, Kim WH, Kim SW. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas. J. Hepatobiliary Pancreat. Surg. 2009;16:668–674.
    1. Liggett T, Melnikov A, Yi Q L, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer. 2010;116:1674–1680.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever